Balstilimab + Botensilimab + Folfox Protocol + XELOX + Nivolumab
Phase 3Recruiting 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Cancer
Conditions
Gastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer
Trial Timeline
Dec 8, 2025 → May 15, 2028
NCT ID
NCT06346197About Balstilimab + Botensilimab + Folfox Protocol + XELOX + Nivolumab
Balstilimab + Botensilimab + Folfox Protocol + XELOX + Nivolumab is a phase 3 stage product being developed by Agenus for Gastric Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06346197. Target conditions include Gastric Cancer, MSI-H, Metastatic Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06346197 | Phase 3 | Recruiting |
Competing Products
20 competing products in Gastric Cancer